Medicinal plants

Qi Health Revolutionizes Women's Health with Evidence-Based Chinese Herbal Medicine

Retrieved on: 
Monday, November 27, 2023
Patient, PCOS, TCM, Woman, Telehealth, Infertility, PMS, Prescription, Herbal medicine, Fertility, Inflammation, Health, Endometriosis, Chinese herbology, PMDD, Qi, CHM, Female, Traditional Chinese medicine, Medicinal plants

Qi Health introduces the first evidence-based digital health platform for herbal medicine, revolutionizing women's well-being with natural solutions.

Key Points: 
  • New York, New York--(Newsfile Corp. - November 27, 2023) - Qi Health , a cutting-edge digital health platform dedicated to Chinese Herbal Medicine (CHM) emerges from beta today.
  • By connecting patients with certified Traditional Chinese Medicine (TCM) doctors in the United States through video calls, Qi Health brings a transformative approach to women's healthcare.
  • In a world where Traditional Chinese Medicine often faces skepticism, Qi Health relies on rigorous research and evidence-based care.
  • Qi Health's vision extends beyond individual care; it aspires to make Traditional Chinese Herbal Medicine accessible to everyone with unexplained or untreated health issues.

HEMP BioSciences Inc. a Wholly-owned Division of WEED Inc. Receives Full Suite of Industrial Hemp Licenses From State of Arizona

Retrieved on: 
Thursday, December 21, 2023
Transporter, Cannabis, Pithing, Sale, Absorption, Nursery, CGMP, Arizona Department, Certification, Oil, Hemp, Harvester, Industrial, HEMP, Processor, OTCQB, IBN, CO2, Medicinal plants

Nicole Marie Breen, COO of HEMP BioSciences Inc., said: “HEMP has been issued all required licenses for Industrial HEMP; Growing, Nursery, Harvester, Transporter and Processor licenses under Title 3-Chapter 2-Article 4.1 of The Arizona Department of Agriculture.

Key Points: 
  • Nicole Marie Breen, COO of HEMP BioSciences Inc., said: “HEMP has been issued all required licenses for Industrial HEMP; Growing, Nursery, Harvester, Transporter and Processor licenses under Title 3-Chapter 2-Article 4.1 of The Arizona Department of Agriculture.
  • With the renewal of our hemp licenses, we are now in the process of acquiring a cGMP certification to ensure the highest quality products, while protecting the public in this highly regulated industry.
  • “HEMP’s proprietary strains vary in phytochemical properties that contain no more than 0.3% THC in dried condition for sale under our current licensing,” Miller continued.
  • “Our products are high in active phytonutrients and are grown, cultivated, harvested and processed in the USA.

Global Nutraceuticals Market Outlook Report 2023-2028 Featuring Prominent Vendors BASF, Herbalife, Flavors & Fragrances, Nestle & Meiji Holdings - ResearchAndMarkets.com

Retrieved on: 
Friday, December 22, 2023
Retail, Fitness & Nutrition, Health, Food, Beverage, BASF, Functional food, Attention, Energy, Athlete, Sale, Food industry, Prevalence, Herbalife, Nutrient, Conditional sentence, Supermarket, USD, Pharmacy, Meiji Holdings, Medicinal plants

The "Nutraceuticals Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nutraceuticals Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global nutraceuticals market is expected to grow at a CAGR of 8.47% from 2022-2028.
  • In addition, across the nutraceutical industry, several domestic, national, and international vendors are present worldwide, showing highly competitive rivalry.
  • Some of the key players in the global nutraceuticals market include BASF, Herbalife, International Flavors & Fragrances Inc. (IFF), Nestle, and Meiji Holdings.

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Retrieved on: 
Tuesday, November 14, 2023
Sale, Acquisition, Safety, Pivotal, EGX, DMT, Entrepreneurship, Aes, Plasma, MDMA, Investment, Exercise, CIAS, Administration, Patient, QT, Research, Cognition, American College, G&A, Pharmacology, OTF, Permeability, Drug discovery, IB, TRD, PTSD, OUD, R, Neuroscience, Research and development, Mental health, AI, Poster, Taste, Pharmaceutical industry, Bank, Medicinal plants, Rare-earth element, Vaccine, Medical device, Psychopharmacology, Anorexia nervosa, Ibogaine

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.

Key Points: 
  • NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.
  • The on-going Phase 2b study will evaluate 20mg and 40mg of RL-007 vs. placebo in patients with CIAS, with topline results expected in 2H 2024.
  • The poster will be presented at the American College of Neuropsychopharmacology (ACNP) annual meeting on Dec 5, 2023, 5:00 – 7:00 PM ET.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc.

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Retrieved on: 
Sunday, December 10, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecular Pharmacology, Fever, Associate, Azacitidine, Hypotension, Safety, CCR, Spacecraft, Pneumonia, ASH, University, Cytopenia, Disease, Cellular, Constipation, Fatigue, Mortality, Penile ultrasonography, Patient, IMGN, DNA, MRD, Medical Affairs Bureau, Pharmacokinetics, Peripheral edema, Flow cytometry, Capillary leak syndrome, MD, Diarrhea, Cancer, Nausea, Survival, Drug resistance, Transplant, AML, Apoptosis, MD Anderson Cancer Center, Society, ImmunoGen, Hypokalemia, Hypophosphatemia, Venetoclax, Rare-earth element, Pharmaceutical industry, Birth control, Vaccine, Medicinal plants, Research

These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

Key Points: 
  • These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
  • “The MRD negativity rates, which are indicative of a deep remission, are particularly promising in the treated patient population.
  • Response rates and MRD negativity were numerically comparable between cohorts 1 and 2, despite differences in the venetoclax schedule.
  • We look forward to continuing to expand our cohort of newly diagnosed unfit patients to inform the development path for pivekimab in AML.”
    ImmunoGen is also presenting two preclinical posters at ASH.

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Retrieved on: 
Wednesday, December 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Capecitabine, Trastuzumab, Senior, Food, Progression-free survival, RECIST, National Comprehensive Cancer Network, Tablet, Breast cancer, Brain, Taxane, Patient, Research and development, PFS, Corr, Division, FDA, Hematology, University, Development, HR, Tucatinib, HER2, Inc., Confidence interval, News, Professor, HIV disease progression rates, Medical imaging, Medicinal plants, Seagen

Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®).

Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®).
  • The combination showed a statistically significant improvement in progression-free survival (PFS), the study’s primary endpoint, in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer who had been previously treated with trastuzumab and a taxane, compared to those who received placebo plus ado-trastuzumab emtansine.
  • Discontinuations due to adverse events were more common in the combination arm of the trial, but no new safety signals were observed for the combination.
  • Please see Important Safety Information at the end of this news release for TUKYSA (tucatinib) tablets.

North America Cannabis Market Report 2023 with Strategic Recommendations - Focus on Gummies and Chocolates, and Developing Products for Therapeutic Use - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023
Hemp, Cannabis, Natural Resources, Research, THC, Porter's five forces analysis, User, Medicine, SWOT, USD, Person, Growth, Drug, Medicinal plants, Retail, CBD

The North America Cannabis market showcased growth at a CAGR of 10.20% during 2019-2022.

Key Points: 
  • The North America Cannabis market showcased growth at a CAGR of 10.20% during 2019-2022.
  • This has led to increased product quality and diversity, ranging from traditional flower products to concentrates, edibles, topicals, and more.
  • E-commerce platforms and online delivery services have gained popularity, allowing consumers to conveniently purchase cannabis products.
  • Licensed producers and dispensaries play a vital role in supplying cannabis products to consumers, both for medical and recreational purposes.

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Status: Authorised

Retrieved on: 
Monday, December 18, 2023
Mantle cell lymphoma, Anatomy, Select, Urine, ATC, Protein kinase inhibitor, Neutrophil, Anemia, BTK, Pneumonia, MCL, International, INN, Disease, Language, Tablet, EMA, Patient, IIA, Marketing, Medical Subject Headings, Diarrhea, Neutropenia, Cancer, Infection, Bruise, Growth, Mouth, Fatigue, Urinary tract infection, Chemotherapy, Instrumentation, Vaccine, Pharmaceutical industry, Medicinal plants, Medical device, Medical imaging, Online shopping, Bookkeeping, Medicine, Lymphoma, Pirtobrutinib

Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021.

Key Points: 
  • Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021.
  • Treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
  • Treatment should be continued until the disease gets worse or the patient gets unacceptable side effects.
  • Jaypirca : EPAR - Medicine overview
    Product information
    Jaypirca : EPAR - Product information
    This medicine’s product information is available in all official EU languages.

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Retrieved on: 
Monday, December 18, 2023
People, Eye, Allergic conjunctivitis, Select, Anatomy, ATC, Safety, European Medicines Agency, Ageing, International, IGA, INN, Disease, Language, Overview, Dry, Patient, IIA, Thigh, Conjunctivitis, Marketing, EASI, Atopic dermatitis, Medical Subject Headings, Diagnosis, Red, Skin, Human, Inflammation, Instrumentation, Medicinal plants, Medical device, Copper, Vaccine, Medical imaging, Online shopping, Bookkeeping, Dermatitis, Medicine

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Retrieved on: 
Monday, December 18, 2023
Carboplatin, Vomiting, Cough, Anatomy, Select, ATC, Safety, Radiation, Neutrophil, European Medicines Agency, Rash, MEK, HGG, International, INN, Headache, Language, Tablet, EMA, Patient, IIA, Marketing, Neoplasm, Medical Subject Headings, Diarrhea, Neutropenia, BRAF, Vincristine, Bleeding, Cancer, Nausea, Water, Growth, Fatigue, Xeroderma, LGG, Fever, Mutation, Cell, Instrumentation, Medical imaging, Pharmaceutical industry, Medicinal plants, Medical device, Vaccine, Mobile phone, Online shopping, Bookkeeping, Glioma, Medicine

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised